Development of innovative microencapsulated products as effective and safe oral administration system of new enzybiotics (enzymes as an alternative to antibiotics to combat pathogenic bacterial infections) and that confer advanced functional and technological characteristics with a high impact in the fight against multidrug-resistant intestinal bacteria E. coli.
The bacterium “Escherichia coli” (E. coli) normally resides in the intestines of humans and animals, some E. coli are pathogenic, that is, they produce diseases, and are responsible for intestinal infections that cause diarrhea or urinary infections, being in some cases even fatal.
E. coli has become the first cause of nosocomial infection and the inadequate use of antibiotics in urinary infections has caused that E. coli has developed antimicrobial resistance.
Gastrointestinal infections are one of the most important causes of morbidity and mortality among infants and children. In Asia, Africa and Latin America, the probability that a child dies before age 5 for these causes can reach 50%.
Thus, the development of new alternative antimicrobial agents and new treatment approaches to eliminate resistant microorganisms and to minimize the appearance of new antibacterial resistance has become an urgent issue.
- Title: PROTEOCAPS: Improvement of the bioavailability of enzymes that can be used as new antibiotics against intestinal human infections caused by Escherichia coli.
- Identification Number: 0011-1365-2019-000140
- Implementation period: April 2019-December 2020
- Partners: NUCAPS Nanotechnology, S.L., IKAN Biotech S.L.
This project has been approved by the Government of Navarre in the R&D projects 2019 call and it is co-financed (50%) by the FEDER funds through the Programa Operativo 2014-2020 de Navarra.
This enterprise has received a 50% co-financed grant by the European Regional Development Fund through the Programa Operativo FEDER 2014-2020 de Navarra.